drugset
Drugs / Trivalent Influenza Vaccine (TIV-2)
last change Mar 2017 re-read 2 minutes ago

Trivalent Influenza Vaccine (TIV-2)

also known as bioCSL TIV-2 · CSL TIV-2 · IIV3-VIC

Vaccine

Developed for
influenza

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02214225 Comparator Aug → Nov 2014 influenza Seqirus Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Trivalent Influenza Vaccine (TIV-2) ClinicalTrials.gov intervention name — accepted as the source's own label NCT02214225 ↗
Known as bioCSL TIV-2 “a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2)” NCT02214225 ↗
Known as CSL TIV-2 “a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2)” NCT02214225 ↗
Known as IIV3-VIC “IIV3 containing the alternate Victoria B strain (IIV3-VIC)” PMID 28302411 ↗ Mar 2017
Modality Vaccine “a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2)” NCT02214225 ↗
Route Intramuscular “One 0.5 mL intramuscular dose into the deltoid muscle.” NCT02214225 ↗